Biotechnology Company NEUROKIN Strengthens its Board of Directors and Scientific Committee

The neuroprotective drugs development company announces today the appointment of two former Vice Presidents of Sanofi - Aventis; Bernard Reculeau, and Jesús Benavides.

scientist studying neurons

Activities

Neurokin exploits the role of specific inhibitors of the cell cycle in neuroprotection. This strategy is based on results demonstrating the therapeutic effects of CDK inhibitors in in vitro models of neuronal death induced by excitotoxicity (due to excessive release of glutamate or its analogs) and in in vivo models of ischemia. Excitotoxicity is a central mechanism in many acute and chronic neurological diseases, as stroke, epilepsy, Parkinson disease and Alzheimer disease.


Neurokin’s objective is to develop a new generation of neuroprotectants for the treatment and the prevention of acute neurological diseases. Neurokin focuses firstly on stroke. Three other development programs are considered in the treatment of pathologies that share same mechanisms of lesions: epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury (TBI).


Featured links

scientist studies neurons cardiac arrest